302-02-008 ISMRM Abstract

Phase-resolved functional lung and 19F MRI detect early treatment response to mepolizumab in patients with severe asthma

Primary: Body - Lung

Secondary: Acquisition & Reconstruction - Quantitative Imaging: chest, abdomen, and pelvis

302-02-008 · Take a Breath: Chest, Thoracic, and Pulmonary MRI · Monday, 11 May, 8:20 AM–10:10 AM · Hall 1B

Keywords: 19F MRI Functional lung imaging PREFUL MRI Asthma Treatment Response Assessment

Accepted

Julienne Scheller ^1,2, Hendrik Suhling^1,3, Arnd J Obert⁴, Marius Klein^1,2, Nora Drick³, Marcel Gutberlet^2,5, Andreas Voskrebenzev^1,2, Peter Howarth⁶, Frank Wacker², Jens Vogel-Claussen^1,2,7

¹Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Munich, Germany

²Institute of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany

³Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany

⁴Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany

⁵Research Campus STIMULATE, Otto-von-Guericke University, Magdeburg, Germany

⁶Specialty Medicine (Respiratory/Immunology), GSK, London, United Kingdom

⁷Department of Radiology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Presenting Author: Julienne Scheller

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. The Lancet. 2012;380:651–9. doi:10.1016/S0140-6736(12)60988-X. [doi]

2. Drick N, Seeliger B, Welte T, et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC Pulm Med. 2018;18(1):119. doi:10.1186/s12890-018-0689-2 [doi]

3. Dohna M, Voskrebenzev A, Klimeš F, et al. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study. Radiol Cardiothorac Imaging. 2024;6(2):e230104. doi:10.1148/ryct.230104 [doi]

4. Obert AJ, Kern AL, Gutberlet M, et al. Volume-Controlled 19 F MR Ventilation Imaging of Fluorinated Gas. J Magn Reson Imaging. 2023;57(4):1114-1128. doi:10.1002/jmri.28385 [doi]

5. Friedlander Y, Munidasa S, Thakar A, et al. Phase-Resolved Functional Lung (PREFUL) MRI to Quantify Ventilation: Feasibility and Physiological Relevance in Severe Asthma. Acad Radiol. 2024;31(8):3416-3426. doi:10.1016/j.acra.2024.01.039 [doi]

6. Milger K, Korn S, Feder C, et al. Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS). Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS). Pneumologie. 2025;79(6):439-451. doi:10.1055/a-2102-8128 [doi]

7. Voskrebenzev A, Gutberlet M, Klimeš F, et al. Feasibility of quantitative regional ventilation and perfusion mapping with phase-resolved functional lung (PREFUL) MRI in healthy volunteers and COPD, CTEPH, and CF patients. Magn Reson Med. 2018;79(4):2306-2314. doi:10.1002/mrm.26893 [doi]

8. Foo CT, Langton D, Donovan GM, et al. Assessment of ventilation heterogeneity in severe asthma using phase-resolved functional lung magnetic resonance imaging. Physiol Rep. 2025;13(12):e70423. doi:10.14814/phy2.70423 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/302-02-008